Captrust Financial Advisors Gilead Sciences, Inc. Transaction History

Captrust Financial Advisors

$30.9 Billion
Q2 2024

A detailed history of Captrust Financial Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 1,630,923 shares of GILD stock, worth $137 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

1,630,923

Previous 1,645,278 0.87%

Holding current value

$137 Million

Previous $121 Million 7.15%

% of portfolio

0.36%

Previous 0.4%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $906,518 - $1.05 Million	-14,355 Reduced 0.87%	1,630,923 $112 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $11 Million - $13.5 Million	154,217 Added 10.34%	1,645,278 $121 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $2.11 Million - $2.4 Million	28,861 Added 1.97%	1,491,061 $121 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $1.83 Million - $2 Million	24,809 Added 1.73%	1,462,200 $110 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $2.35 Million - $2.68 Million	30,854 Added 2.19%	1,437,391 $111 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $5.03 Million - $5.73 Million	65,042 Added 4.85%	1,406,537 $117 Million
Q4 2022 Feb 15, 2023	SELL	$62.32 - $89.47 $4.12 Million - $5.92 Million	-66,157 Reduced 4.7%	1,341,495 $115 Million
Q3 2022 Nov 16, 2022	BUY	$59.54 - $68.01 $7.66 Million - $8.75 Million	128,656 Added 10.06%	1,407,652 $86.8 Million
Q2 2022 Aug 23, 2022	SELL	$57.72 - $65.01 $1.76 Million - $1.99 Million	-30,570 Reduced 2.33%	1,278,996 $79.1 Million
Q2 2022 Aug 16, 2022	BUY	$57.72 - $65.01 $11.1 Million - $12.6 Million	193,105 Added 17.3%	1,309,566 $80.9 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $7.46 Million - $9.34 Million	128,748 Added 13.03%	1,116,461 $66.4 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $2.9 Million - $3.29 Million	44,649 Added 4.73%	987,713 $71.7 Million
Q3 2021 Nov 16, 2021	BUY	$67.69 - $73.03 $5.64 Million - $6.08 Million	83,250 Added 9.68%	943,064 $65.9 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $4.86 Million - $5.31 Million	76,532 Added 9.77%	859,814 $59.2 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $3.94 Million - $4.49 Million	65,609 Added 9.14%	783,282 $50.6 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $25.1 Million - $28.6 Million	442,550 Added 160.86%	717,673 $41.8 Million
Q3 2020 Nov 17, 2020	BUY	$62.1 - $78.08 $15.1 Million - $19 Million	242,957 Added 755.32%	275,123 $17.4 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $42,029 - $48,804	581 Added 1.84%	32,166 $2.45 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $417,742 - $535,067	-6,670 Reduced 17.44%	31,585 $2.29 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $1.65 Million - $1.82 Million	26,805 Added 234.1%	38,255 $2.5 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $18,878 - $20,838	-302 Reduced 2.57%	11,450 $726,000
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $80,864 - $90,679	1,307 Added 12.51%	11,752 $794,000
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $135,690 - $152,008	2,170 Added 26.22%	10,445 $679,000
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $170,480 - $222,464	-2,816 Reduced 25.39%	8,275 $518,000
Q3 2018 Nov 15, 2018	BUY	$71.28 - $78.92 $171,072 - $189,408	2,400 Added 27.61%	11,091 $856,000
Q2 2018 Aug 13, 2018	SELL	$64.88 - $75.68 $38,019 - $44,348	-586 Reduced 6.32%	8,691 $616,000
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $160,757 - $195,981	2,207 Added 31.22%	9,277 $679,000
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $60,121 - $70,574	845 Added 13.57%	7,070 $506,000
Q3 2017 Feb 16, 2018	BUY	$72.11 - $85.47 $448,884 - $532,050	6,225	6,225 $503,000

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Gilead Sciences, Inc. Transaction History